Blockbuster weight-loss medications, collectively known as GLP-1s, including Mounjaro, Wegovy, and Ozempic, have gained widespread popularity for their ability to induce rapid weight loss, with millions in the UK using them weekly. These injections, which can help users lose up to a fifth of their body weight, have revolutionized obesity treatment. However, experts are increasingly warning that these drugs may not be the quick fix many believe them to be, citing significant challenges related to weight regain, diverse side effects, pricing, and the need for strict medical oversight.

A primary concern highlighted by metabolic medicine experts, including those fromPeking University People's Hospital, is the rapid weight regain experienced by users within just eight weeks of stopping treatment. Even with newer, more potent jabs like Mounjaro (trizeparide), patients were found to regain nearly half the weight they had lost after ceasing the drug and switching to a placebo.

This phenomenon, termed 'weight cycling,' is speculated to be caused by adverse hormonal changes in the gut that increase hunger levels, as well as a lack of effective behavioral strategies once the self-restraint provided by the drugs is removed. Tam Fry, chairman of the National Obesity Forum, emphasizes that GLP-1s are not a quick fix without parallel lifestyle improvements.

Photo Credit: Science News

The efficacy of these drugs is often accompanied by a range of side effects, some common and others severe. Common adverse reactions include nausea, constipation, and diarrhea. More serious complications reported by users and medical professionals include gallstones, pancreatitis (inflammation of the pancreas), and gastroparesis (stomach paralysis), where food is not digested properly, sometimes necessitating surgery. One in five users reportedly discontinue the drugs within a year due to these intolerable side effects.

Emerging concerns also point to dental issues, dubbed 'Ozempic teeth,' which include tooth decay, receding gums, sensitivity, and even tooth loss. This is attributed to increased acid reflux caused by the drugs slowing digestion, and dry mouth (xerostomia), which reduces saliva's protective role. Hope Lancaster Colquhoun's experience of losing multiple teeth after significant weight loss on Mounjaro exemplifies this distressing side effect, leading to over £3,700 in dental costs. Additionally, diet choices on these medications, often favoring softer, processed foods, may exacerbate oral health problems.

Controversially, recent research tracking nearly 44,000 overweight and obese individuals for up to ten years found a mixed impact on cancer risk. While GLP-1 drugs were linked to a 17 percent lower risk of overall cancer, with significant drops in ovarian and womb tumors, they were also associated with a disturbing one-third higher likelihood of developing kidney cancer, particularly among under-65s and overweight individuals. Theories for this uptick include repeated bouts of acute kidney injury from dehydration or overstimulation of GLP-1 receptors in the kidneys. Despite these concerns, experts caution against over-interpreting the data and emphasize the need for more research, noting the drugs' proven benefits in reducing the risk of heart attacks, strokes, and kidney disease.

In response to varying patient experiences and side effects, new technologies are being explored. The Gastric Alimetry pad, a non-invasive stick-on device, measures the stomach's electrical activity (electrogastrogram) to determine its emptying rate. This allows doctors to identify the 'sweet spot' for dosing, minimizing side effects like nausea and vomiting while maximizing weight loss, potentially reducing the high drop-out rate. The device, though costly at £1,875 for private testing, offers a precise alternative to current guesswork in dose adjustment. Other suggested remedies for nausea include eating specific foods like crackers or mint, and using acupressure wristbands.

The economic landscape of these treatments is also shifting. Eli Lilly confirmed steep price increases for Mounjaro in the UK from September 1st, with the highest 15mg dose soaring by 170 percent from £122 to £330 a month. This has prompted many of the estimated 625,000 Mounjaro users to consider switching to cheaper alternatives like Wegovy.

Dr. Donald Grant, GP, and other medical experts stress that transitioning between these drugs must be done under strict medical supervision due to differing strengths and to mitigate severe side effects. Warnings have also been issued against 'cowboy operators' exploiting the situation by selling illicit or incorrect dosages online.

Beyond medical and financial considerations, the use of weight-loss jabs also presents psychological and relational challenges. Many users, predominantly women, secretly take these medications from their partners due to fears of disapproval or constant questioning about side effects. Experts, including Dr. Rose Aghdami from the British Psychological Societyand surgeon Zaher Toumi, warn of the emotional toll of secrecy, potentially leading to feelings of deception and betrayal for partners.

Photo Credit: CBC News

Furthermore, non-disclosure to partners and GPs can pose physical dangers, such as drug interactions with contraceptives or blood thinners, and delayed recognition of severe side effects like pancreatitis, which require timely intervention.

In a significant shift, the National Institute for Health and Care Excellence (NICE) has issued new guidelines for Type 2 diabetes treatment. These recommendations advocate for a more 'holistic' and personalized approach, including the earlier use of weight-loss drugs like Ozempic (semaglutide) and SGLT-2 inhibitors as first-line treatments.

This move aims to prevent severe complications such as heart attacks, strokes, and kidney disease, particularly for adults with cardiovascular disease or those diagnosed with Type 2 diabetes before age 40. The guidelines also seek to address existing prescribing gaps, especially among women, older individuals, and Black patients, potentially saving thousands of lives and reducing health inequalities, according to Professor Jonathan Benger of NICE and Douglas Twenefour of Diabetes UK.

Ultimately, while GLP-1 weight-loss jabs offer transformative potential for managing obesity and associated health conditions, their long-term effectiveness, diverse side effect profile, evolving cost, and the critical need for medical guidance and lifestyle integration present a complex and multifaceted picture. Users are urged to maintain open communication with healthcare providers and to be aware of both the benefits and risks associated with these powerful medications.